Clinical Trial

Study on the Efficacy and Safety of Mecobalamin in Preventing Taxane-related Peripheral Neuropathy

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Some patients receiving taxane-based chemotherapy experience numbness, tingling, or pain in their hands and feet, known as chemotherapy-induced peripheral neuropathy (CIPN). This study aims to find out whether oral mecobalamin can prevent or reduce CIPN. Participants will be assigned to take mecobalamin or to receive no routine mecobalamin prevention during chemotherapy, and outcomes will be compared between groups.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2026-02-19; most recent amendment 2026-04-25.
Status change: Not Yet Recruiting → Recruiting 2026-02-28
Trial Details
NCT Number NCT07423390
Lead Sponsor Qinghai Red Cross Hospital
Conditions Peripheral Neuropathy Due to Chemotherapy, Peripheral Neuropathy, Chemotherapy-induced
Enrollment 326 participants
Start Date 2026-02-24
Primary Completion 2029-03-30 (estimated)
Study Completion 2029-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-30